Generally, the studies that report a change in plasma fasting FGF21 were performed in individuals with more severely impaired metabolic health (e.g., T2DM, NAFLD, morbid obesity), who typically have elevated FGF21 levels and thus more room for improvement compared to individuals in this study. The gene discussed is FGF21; the disease is type 2 diabetes mellitus.